DE4004061A1 - NEW IMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS, AND SOME INTERMEDIATE PRODUCTS - Google Patents

Abstract

Imidazole derivs. of formula (I) and their salts are new. R1 = 1-6C alkyl. R2, R3 = independently H, F, Cl, Br, I or 1-3C alkyl. X = OH or -NR4R5. R4 = H or 1-7(1-4)C alkyl, opt. substd. by CN, NH2 or CO2H. R5 = 1-8 (1-5)C alkyl, opt. interrupted by phenyl and opt. substd. by not less than 1 OH, 1-3C alkoxy, (un)substd. phenyl, CO2H, CO2-(1-3C alkyl), -CONH2, CN, 2-5C alkynyl, NH2, NHR6, N(R6)2, N+(R6)3, NH-CO-(1-6C alkyl), a gp. of formula (i), a monocyclic 5-7 membered (un)saturated opt. substd. heterocycle with one N heteroatom, and opt. an extra N, O or S heteroatom, where the S atom can be oxidised to SO or SO2. Alternatively, R4 and R5 together form a 5-7 membered opt. substd. heterocycle which may contain, in addn. to the amide N atom, a further N, O or S heteroatom. The heterocycle is not morpholine. R6 = independently 1-4C alkyl, 2-6C alkoxyalkyl or phenyl-(1-3C alkyl). N-(2-morpholinoethyl)-1-methyl -2-imidazolsulphonic acid amide and N-(2-morpholinopropyl) -1-methyl-4-imidazolsulphonic acid amide are specifically claimed. Also claimed.are methods for preparing (I), e.g. by sulphonation of the corresponding mono-, di- or trisubstituted imidazole cpd.

Description

Diseases of the circulatory system have been reported in recent years Years with over 50% at the top of all deaths. Here again thromboembolic predominated Complications. Despite intensive worldwide efforts to Progress in the elucidation of causes of disease, Characterization and detection of relevant risk factors and The development of reliable treatment methods is still lacking satisfactory drug therapy (L. Harker, in: Seminars in Thrombosis and Hemostasis, Vol. 12, No. 2, 134-155, 1986; de Gaetano et al., in: Current issues in thrombosis prevention with antiplatelet drugs, 31, 517-549, 1986). The overarching goal of an antithrombotic, anti-ischemic therapy is the correction of the disturbed Organ functions (e.g. muscle performance in claudication intermittens) and thus an improvement in the quality of life by preventing early disability and ultimately preventing lethal events.

Around 5% of all people over the age of 50 suffer from peripheral ones Circulatory disorders, of which a good 10% are at risk, a critical limb ischemia (CLI = critical limb ischemia) to develop. The incidence of the CLI is approximately 500 to 1000 per 1 million people a year. About 60% these patients receive vascular replacement, but about 20% suffer the fate of a primary amputation. A year later only about 55% of the patients own both lower extremities, but about 25% already have one Amputation behind and the rest of the patients are deceased. This short presentation shows in impressive Way the need for early and effective  drug treatment of peripheral occlusive diseases on.

The previously known imidazole sulfonamides are said to mainly have herbicidal or biocidal properties (cf. CA-A 12 22 752 corresponding to EP-A 96 003; EP-A 95 925, EP-A 02 98 196 and EP-A 2 49 938), as textile auxiliaries or plasticizers for plastics are suitable (US Pat. No. 3,932,444) or also act as carbonic anhydrase inhibitors (US-A 26 03 649).

It has now been found that a number of new Imidazole compounds (imidazole sulfonic acids and Imidazole sulfonamides) surprisingly very valuable have pharmacological properties, in particular those who have prophylaxis and treatment of Circulatory disorders, especially disorders of the Microcirculation and the resulting diseases enable. These are the connections of the following formula I; these connections and their Physiologically acceptable salts are therefore the subject of present invention.

Formula I is

in which
R¹ = (C₁-C₆) alkyl,
R², R³ = identical or different and each = H, halogen (F, Cl, Br, J), preferably Cl, or (C₁-C₃) alkyl,
X = OH or an amino group of the formula II

wherein
R⁴ = H or (C₁-C₇) -, preferably (C₁-C₄) alkyl, optionally substituted with CN, NH₂ or COOH
R⁵ = (C₁-C₈) -, preferably (C₁-C₅) -alkyl radical, in which - if it has more than 1 carbon atom - a phenylene radical can also be between 2 carbon atoms and whose (aliphatic) carbon atoms are substituted are with 1 or more of the following groups:
OH, (C₁-C₃) alkoxy, phenyl, optionally substituted with 1-3 OH-, (C₁-C₃) alkoxy groups, (C₁-C₃) alkoxy-COOH, and / or (C₁-C₃) alkoxy- COO (C₁-C₄) alkyl, COOH, COO (C₁-C₃) alkyl, CONH₂, CN, (C₂-C₅) alkynyl, NH₂, NHR⁶
N (R⁶) ₂
N⊕ (R⁶) ₃
wherein R⁶ same or different residues of the type
(C₁-C₄) alkyl
(C₂-C₆) alkoxyalkyl and
Phenylalkyl with 1-3 carbon atoms in the alkyl part means
NH-CO- (C₁-C₆) alkyl,

(Meaning of R¹, R² and R³ as above),
monocyclic 5- to 7-membered saturated or unsaturated - preferably saturated - heterocyclic radicals with 1 N atom and optionally also an additional N, O or S atom in the ring, optionally substituted with (C₁-C₃) alkyl, phenyl, phenylalkyl with 1-3 C atoms in the alkyl part, OH, and / or oxo (= O), including the open and cyclic ketal forms with 2-6 C atoms in the ketal part, and in which the ring S atom - if present - also can be oxidized to the sulfoxide (SO) - or sulfone (SO₂) form, or in which R⁴ and R⁵ together with the amide N atom to which they are attached form a - preferably saturated - 5- to 7-membered heterocyclic ring, which, in addition to the amide-N, can also contain a further heteroatom from the group N, O and S in the ring, although the unsubstituted morpholine ring

is excluded and the heterocyclic ring can otherwise be substituted with the following groups:
(C₁-C₃) alkoxy, phenylalkyl with 1-4 C atoms in the alkyl part, phenyl, optionally substituted with 1 or more - preferably only 1 - of the groups:
(C₁-C₃) alkyl, OH, (C₁-C₃) alkoxy, (C₁-C₃) alkoxy-COOH, (C₁-C₃) alkoxy-COO (C₁-C₄) alkyl,

O-SO₂-C₆H₅
O-SO₂-C₆H₄CH₃,

in which R ^{1 'has} the same meaning as R¹ and may additionally be = H, and R² and R³ have the abovementioned meaning, and the ring S atom - if present - also for sulfoxide (SO) - or sulfone (SO₂) -Form can be oxidized.

Preferred compounds of the formula I are those in which at least one of the following features is present:
a) R¹ = CH₃ or C₂H₅
b) R², R³ = identical or different and each H, Cl or CH₃ and
c) the -SO₂X radical is in the 2- or 4-position of the imidazole ring.

Furthermore, among the compounds of formula I Preferred sulfonamides; d. s. so the connections with

where the radicals R⁴ and R⁵ preferably have the following meaning:
R⁴ = H and
R⁵ = (C₂-C₅) alkyl, in which a phenylene radical is optionally between 2 C atoms and whose (aliphatic) C atoms are substituted with a total of 1 or 2 - preferably only 1 - of the following groups:
Hydroxyphenyl C₆H₄OH, CN, (C₂-C₃) alkynyl, NH₂
NHR⁶
N (R⁶) ₂
wherein R⁶ = identical or different radicals of the type
(C₁-C₃) alkyl,
(C₂-C₄) alkoxyalkyl and benzyl;
monocyclic 5- to 6-membered saturated heterocyclic radical from the group:

or R⁴ and R⁵ together with the amide N atom to which they are attached are bound, a saturated 6-membered heterocyclic ring form the kind

Among the sulfonamides are those with separate ones Residues R⁴ and R⁵ compared to those with - together with the Amide-N - R bevorzugt + R⁵ closed to form a ring somewhat preferred.

Particularly preferred compounds of the formula I are N- (2-morpholinoethyl) -1-methyl-2-imidazolesulfonamide = compound of the formula I, in which
R¹ = CH₃,
R² = R³ = H,
SO₂X group in 2 position and

such as
N- (3-morpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide = compound of formula I, wherein
R¹ = CH₃,
R² = R³ = H,
SO₂X group in 4 position and

As physiologically acceptable salts such. B. in question:
- If acidic groups are present in the compounds of the formula I (in particular if X = OH):
Na, K, NH₄ salts etc;
- If basic groups are present in the compounds of the formula I:
Hydrochloride, salts with physiologically compatible organic acids (acetic acid, maleic acid, fumaric acid etc.), etc.

Some exemplary compounds of the formula I according to the invention - both not particularly preferred and preferred - are:
1-methyl-4-imidazole sulfonic acid,
1-ethyl-4-imidazole sulfonic acid,
1-methyl-2-imidazole sulfonic acid,
5-chloro-1-methyl-4-imidazole sulfonic acid,
2-fluoro-1-methyl-4-imidazole sulfonic acid,
4-chloro-1-methyl-5-imidazole sulfonic acid,
1-methyl-5-imidazole sulfonic acid,
1,2-dimethyl-5-imidazole sulfonic acid,
N- (3-morpholinopropyl) -1-methyl-4-imidazolesulfonamide,
N- (2-morpholinoethyl) -1-methyl-4-imidazolesulfonamide,
N- (4-morpholinobutyl) -1-methyl-4-imidazolesulfonamide,
N- (5-morpholinopentyl) -1-methyl-4-imidazolesulfonamide,
N- (3-morpholino-2-methyl-1-propyl) -1-methyl-4-imidazolesulfonic acid amid,
N- (3-thiomorpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide,
N-butyl-N- (3-morpholino-1-propyl) -1-methyl-4-imidazolesulfonamide,
N- (2-piperidinoethyl) -1-methyl-4-imidazolesulfonamide,
N- [3- (2-methylpiperidino) propyl] -1-methyl-4-imidazolesulfonamide,
N- (5-piperidinopentyl) -1-methyl-4-imidazolesulfonamide,
N- [8-aza-1,4-dioxa-spiro (4,5) decyl] -1-methyl-4-imidazolesulfonic acid am-id,
N- (2-pyrrolidinoethyl) -1-methyl-4-imidazolesulfonamide,
N- [2- (1-methyl-2-pyrrolidinyl) ethyl] -1-methyl-4-imidazolesulfonic acid amide,
N <3- [bis- (2-methoxyethyl) amino] propyl <-4-imidazolesulfonamide,
N- [4- (4-hydroxyphenyl) piperazino] -1-methyl-4-imidazolesulfonic acid amid,
N- [3- (4-benzyl-1-piperazinyl) propyl] -1-methyl-4-imidazolesulfonic acid amide,
N- [3- (4-methylpiperazino) propyl] -1-methyl-4-imidazolesulfonamide,
N- [3- (N-benzyl-N-methylamino) -1-propyl] -1-methyl-4-imidazolesulfonic acid reamide,
N- (3-morpholinopropyl) -1-methyl-2-imidazolesulfonamide,
N- (2-morpholinoethyl) -1-methyl-2-imidazolesulfonamide,
N- (3-morpholinopropyl) -4-chloro-1-methyl-5-imidazolesulfonamide,
N- (3-morpholinopropyl) -5-chloro-1-methyl-4-imidazolesulfonamide,
N- (3-morpholinopropyl) -1,2-dimethyl-4-imidazolesulfonamide,
N- (5-morpholino-1-pentyl) -5-chloro-1-methyl-4-imidazolesulfonamide,
N- (3-morpholinopropyl) -1-propyl-4-imidazolesulfonic acid amide,
N- (3-morpholinopropyl) -1-propyl-5-imidazolesulfonamide,
N- (3-morpholinopropyl) -1-n-butyl-4-imidazolesulfonic acid amide,
N- (3-morpholinopropyl) -1-n-butyl-5-imidazolesulfonic acid amide,
N- (3-morpholinopropyl) -1-ethyl-4-imidazolesulfonamide,
N- (1,3-dimorpholino-2-propyl) -1-methyl-4-imidazolesulfonamide,
N- [4- (4-hydroxyphenyl) piperazino] -5-chloro-1-methyl-4-imidazolesulfonamide,
1- (1-methyl-5-chloro-4-imidazolesulfonyl) -4- [4- (1-methyl-5-chloro-4-imidazolesulfonyloxy) phenyl] piperazine,
4- (1-methyl-4-imidazolesulfonyl) tetrahydro-4H-1,4-thiazine,
1- [3- (1-methyl-5-imidazolesulfonyl) aminopropyl] -2-pyrrolidinone,
N- (3-methoxypropyl) -1-methyl-4-imidazolesulfonamide,
N- (4-hydroxyphenethyl) -1-methyl-4-imidazolesulfonamide,
N- (4-hydroxyphenethyl) -5-chloro-1-methyl-4-imidazolesulfonamide,
1,6-bis (5-chloro-1-methyl-4-imidazolesulfonamido) hexane,
N- (2-cyanoethyl) -1-methyl-4-imidazolesulfonamide,
N- (5-cyanopentyl-1-methyl-4-imidazolesulfonamide,
N- (3-propargyl) -1-methyl-4-imidazolesulfonamide,
4- [2- (1-methyl-4-imidazolesulfonyl) aminoethyl] phenoxyacetic acid,
4- [2- (5-chloro-1-methyl-4-imidazolesulfonyl) aminoethyl] phenoxyacetic acid,
N- (3-morpholino-1-propyl) -1-methyl-5-imidazolesulfonamide,
1,6-bis (1-methyl-4-imidazolesulfonamido) hexane,
N- [3- (1-piperazinyl) propyl] -1-methyl-4-imidazolesulfonamide,
4-methyl-4- [3- (1-methyl-4-imidazolesulfamoyl) -1-propyl] morpholinium iodide,
4- (1-methyl-4-imidazolesulfonyl) tetrahydro-4H-1,4-thiazine-1,1-dioxide,
4- [4- (5-chloro-1-methyl-4-imidazolesulfonyl) piperazin-1-yl] phenoxyacetic acid ethyl ester,
N- (6-aminohexyl) -1-methyl-4-imidazolesulfonamide,
N- (3-aminopropyl) -1-methyl-4-imidazolesulfonamide,
N- (3-thiomorpholinopropyl) -1-methyl-4-imidazolesulfonamide S-oxide,
N- (3-methylamino-1-propyl) -1-methyl-4-imidazolesulfonamide,
N- [4- (morpholinomethyl) benzyl] -1-methyl-4-imidazolesulfonamide,
N- (3-dibenzylaminopropyl) -1-methyl-4-imidazolesulfonic acid amide,
N- (3-dimethylaminopropyl) -1-methyl-4-imidazolesulfonamide,
N- (3-N-ethyl-N-isopropylaminopropyl) -1-methyl-4-imidazolesulfonic acid amide,
N- [bis (2-cyanoethyl)] - 1-methyl-4-imidazolesulfonic acid amide,
N- [2- (2-pyridyl) ethyl] -1-methyl-4-imidazolesulfonamide,
N- (5-carboxypentyl) -1-methyl-4-imidazolesulfonamide and
N- (5-acetylpentyl) -1-methyl-4-imidazole sulfonic acid amide.

The compounds of formula I and their physiological compatible salts according to the invention made that one

a) an imidazole derivative of the general formula III

in which R¹, R² and R³ have the meaning given for formula I. have, and one of the positions 4 or 5 unsubstituted by sulfonation using sulfuric acid or oleum, preferably at temperatures of about 150-180 ° C in the converts compounds of the formula Ia according to the invention,

wherein R¹, R² and R³ also have the meaning given for formula I,
or that one

b) an imidazole derivative of the general formula IV,

in which R¹ and R² have the meaning given for formula I. have one of the positions 4 and 5 a halogen atom (Cl, Br, J) and the other is unsubstituted, by sulfonation and subsequent hydrogenolytic Dehalogenation using precious metal catalysts, preferably at hydrogen pressures of about 1-5 bar polar solvents such as alcohol and / or water and Room temperature to about 60 ° C in a compound of Formula Ib converts

(Meaning of R¹ and R² as in formula I) - temporary protection of the 4- or 5-position prevents sulfonation at this point and thus leads to uniform products - or that one

c) an imidazole derivative of the general formula V,

in which R¹, R² and R³ have the meaning given for formula I. have and Y represents halogen, preferably chlorine, to the Sulfonic acids of the formula Ia according to the invention with the there meanings mentioned for R¹, R² and R³ - preferred with water at room temperature - hydrolyzed, or that one

d) an imidazole derivative of the general formula VI or VI ',

wherein R¹, R² and R³ have the meaning given for formula I. have to the corresponding imidazole sulfonic acid (formula Ia) oxidized, preferably by using the method according to EP-A 95 925 with chlorine to an intermediate imidazole sulfonyl chloride oxidized and then immediately in aqueous Can hydrolyze medium, or that one

e) an imidazole sulfonic acid halide of the general formula V (see variant c), with an amine of the formula H-II,

in which R⁴ and R⁵ have the same meaning as in Formula II have to the sulfonamides of the formula Ic implements

wherein R¹ to R⁵ those mentioned in formulas I and II Have meanings.  

This reaction can occur in the absence of additional acid scavengers are carried out, with the Sales of di- and polyamines the corresponding Hydrochlorides are formed, which are either isolated as such or can be transferred to the free bases, which again either isolated as such or in other salts, for example, that of fumaric acid can be transferred.

On the other hand, the reaction can also take place in the presence of Acid scavengers, such as an excess of the amine to be reacted H-N (R⁴) R⁵ (formula H-II), a lower tertiary amine such as Triethylamine, or inorganic bases such as potassium carbonate respectively.

The sulfonamide formation can occur in an anhydrous, opposite solvent inert to the reactants, preferred Acetonitrile or dichloromethane, if the procedure is suitable however also in protic solvents, for example Water or phenol, each at temperatures between about -30 ° C and the boiling point of the applied Solvent, but preferably between about 0 ° C and 30 ° C, are carried out.

The starting materials in these process variants Most of the amines of formula H-II used are known or can be made using methods known from the literature produce, mainly by hydrogenation or reduction appropriately substituted nitriles. In cases where the hydrogenation is not applicable, for example the phthalimide method can be used. So be as Example given that N- (3-bromopropyl) phthalimide with Thiomorpholine to N- (3-thiomorpholinopropyl) phthalimide reacts, which by hydrazine and subsequent Hydrochloric acid exposure to the hydrochloride of N- (3-aminopropyl) - thiomorpholins can be transferred.  

Furthermore, the compounds of formula I and their physiologically acceptable salts according to the invention made that one

f) imidazole derivatives of the general formula VII,

wherein R¹ and R² have the meaning given for formula I. and Y have the same or different halogen atoms (Cl, Br, J) means reacted with amines of the formula H-II and then the hydrogenolytic Dehalogenation, preferably via Precious metal catalysts, such as palladium on carbon, subjects to the 4- or 5-position to obtain unsubstituted sulfonamides of the formula Id

(Meaning of R¹, R², R⁴ and R⁵ as in formulas I and II), or that one

g) an imidazole sulfonyl halide of the general formula V (see variant c) with a trialkylsilylamine Formula VIII,

where R⁴ and R⁵ have the meaning given in formula II have and more preferably (C₁-C₃) alkyl radical the methyl radical is, brings to implementation to the invention Sulfonamides of the formula Ic (see variant e) receive.

The silylated amines can either be pure Compounds or as fresh - e.g. B. using MSTFA (N-methyl-N-trimethylsilyltrifluoroacetamide) Raw products are used. The reaction with the respective imidazole sulfonyl halide V. usually in inert solvents such as dichloromethane or acetonitrile, at temperatures between about -30 to about 120 ° C, preferably between about -30 ° C and the Boiling point of the solvent. This procedure delivers directly the free base and is also shown at less reactive and sensitive connections.

h) Furthermore, compounds of the invention according to formula I (with X = -N (R⁴) R⁵, where R⁴ has at least one NH₂ group and / or R⁵ at least one primary or secondary Amino group carries) and their physiologically acceptable Salts are represented by the fact that amines of the formula N-N (R⁴) R⁵, the residues R⁴ and / or R⁵ at least an N-protected - preferably N-benzylated - wear the corresponding amino group with the Imidazole sulfonyl halides of the formula V (see variant c), as described under e), implemented and the sulfonamides formed subsequently by the or Protecting group (s) are freed, in the case of N-benzyl Protecting group preferred by hydrogenolysis low hydrogen pressures (about 1-5 bar), little elevated temperatures (room temperature to about 60 ° C) and in ethanolic aqueous ammonia solution Precious metal catalysts, such as palladium on carbon.  

From the number of protective groups which are suitable for protecting the second amino group against attack by an imidazole sulfonyl halide and which can subsequently be removed, the following - apart from the preferred benzyl group already mentioned - should also be emphasized:
Triphenylmethyl, trifluoroacetyl, benzyloxycarbonyl, tert-butyloxycarbonyl, phthalyl, formyl and acetyl.

i) Furthermore, such imidazole derivatives of the formula I with X = -N (R⁴) R⁵, at least one of the radicals R⁴ and R⁵ carries one or more primary amino groups, by making imidazole sulfonyl halides Formula V (see variant c) with corresponding Aminonitriles analogous to the procedure according to variant e) implemented and the so obtained Imidazolesulfonylaminonitrile to corresponding Amino compounds reduced, preferably by catalytic Hydrogenation using precious metal catalysts like palladium on carbon in alcoholic-ammoniacal Solution with increased hydrogen pressure (about 2-5 bar) Room temperature to slightly elevated temperature (up to about 60 ° C).

j) In addition, imidazole derivatives of the formula I can be used X = -N (R⁴) R⁵, where R⁵ is a quaternary Amino group -N⊕ (R⁶) ₃, in which the radicals R⁶ may be the same or different, as follows represent:

The compounds of formula I with tertiary amino groups -N (R⁶) ₂ as a substituent of R⁵ are by means of a Alkylating agents such as alkyl halide are preferred Iodomethane, a sulfuric acid ester, is preferred  Dimethyl sulfate or an aryl sulfonic acid ester, preferably methyl p-toluenesulfonate, in Solvents such as nitromethane, acetonitrile, alcohols or aqueous-alcoholic solutions, preferably in the range from room temperature to the boiling point of Solvent, quaternized.

k) Other substances according to the invention can be produce by using imidazole derivatives of the general Formula I with X = -N (R⁴) R⁵, where R⁵ or R⁴ + R⁵ together supports at least one sulfide group, preferred in the form of a thiomorpholine ring corresponding sulfoxides or sulfones oxidized. Suitable oxidizing agents for this are sodium iodate in aqueous methanolic solution or peroxides such as m-chloroperoxybenzoic acid, peracetic acid or Hydrogen peroxide in solvents such as chloroform or Acetic acid or water.

l) Some of the compounds of formula I can be by synthesizing that Imidazole derivatives of the general formula I mi X = -N (R⁴) R⁵, where R⁵ or R⁴ + R⁵ together at least carry an aryl residue with one or more phenolic hydroxyl groups is substituted with Alkylating reagents, preferred ω-halogen fatty acid derivatives, to the corresponding Phenol ethers alkylated in the presence of basic Compounds, such as sodium hydroxide, in a polar Solvents, such as ethanol, in the temperature range of about 0 ° C to the boiling point of the solvent.

Are the products derivatives of the ω-fatty acid esters, can this still the acidic or alkaline Hydrolysis under standard conditions or aminolysis  with ammonia solutions or solutions from lower primary ones or secondary amines, preferably methylamine, be subjected to the corresponding carboxylic acids or to give carboxamides.

m) These phenolic imidazole derivatives mentioned under l) can also be used with acylation agents such as Alkyl carboxylic acid chlorides, preferably those of Acetic, propionic or butyric acid, with arylsulfonic acid chlorides, preferably benzene or Toluenesulfonic acid chloride, and with imidazolesulfonic acid halides the general formula V (see variant c), in which R¹ can also be hydrogen, too implement the corresponding phenol esters. Appropriately are basic water-free conditions.

The compounds of formula I and their physiological Compatible salts are suitable because of their valuable pharmacological properties very good for use as Remedies.

The subject of the invention are therefore also pharmaceuticals with a Content of at least one compound of formula I and / or at least one of their physiologically acceptable ones Salt. The drugs are preferably suitable for Prophylaxis and / or therapy of circulatory disorders, in particular of disorders of the microcirculation and the resulting diseases.

Those from circulatory disorders, especially from disorders diseases resulting from the microcirculation mainly ischemic skeletal and / or Heart muscle diseases, especially claudication intermittent, leg ulcers and degenerative and / or inflammatory muscle diseases of various origins  or without muscular atrophy, vasculitis with thrombotic Events, arterial and venous blood clots (e.g. Thrombosis, shock).

Because of the blood circulation promoting effect of compounds and medicaments according to the invention, especially in the micro range, are the connections and Medicines also effective in atherosclerosis in which Postoperative treatment to prevent postoperative Thrombosis, for the treatment of cancer Prevention or reduction of metastasis, in the treatment of patients suffering from cardiopulmonary Machines or kidney dialysis are connected and finally also from patients after stroke or Heart attack as well as for wound healing after trauma and exogenous noxa.

The pharmaceuticals according to the invention are generally administered orally or parenterally, but also a rectal In principle, application is possible. Suitable fixed or Liquid pharmaceutical preparation forms are for example Granules, powder, tablets, coated tablets, (micro) capsules, Suppositories, syrups, emulsions, suspensions, aerosols, Drops or injectable ampoule solutions as well Preparations with a protracted release of active ingredients, in their Manufacturing usually carriers and additives and / or Aids such as blasting, binding, coating, swelling, Lubricants or lubricants, flavorings, sweeteners or solubilizers are used. As often Carriers or auxiliaries used are, for. B. magnesium carbonate, Titanium dioxide, lactose, mannitol and other sugars, Talc, milk protein, gelatin, starch, vitamins, cellulose and their derivatives, animal and vegetable oils, Polyethylene glycols and solvents such as sterile Water, alcohols, glycerin and polyhydric alcohols called.  

The pharmaceutical preparations are preferably used in Dosage units prepared and administered, each Unit as an active ingredient a certain dose at least one compound of formula I and / or at least one corresponding physiologically compatible Contains salt. With fixed dosage units such as Tablets, capsules and suppositories can increase this dose about 500 mg, but preferably about 50 to 300 mg, and for injection solutions in ampoule form up to about 150 mg, but preferably about 10 to 100 mg. Between the doses of the compounds of formula I and their There are only slight differences between salts.

For the treatment of an adult patient - are after effectiveness of the compounds of formula I am People - daily doses of about 20 to 500 mg of active ingredient, preferably about 50 to 300 mg when administered orally and from about 5 to 300 mg, preferably about 10 to 100 mg intravenous administration indicated. Maybe you can however, higher or lower temperatures are also appropriate be. The administration of the daily dose can be done both by Single dose in the form of a single dosage unit or but several smaller dosage units as well Multiple administration of divided doses at certain intervals respectively.

The pharmaceuticals according to the invention are thereby prepared that one at least one compound of the formula I and / or at least one of their physiological tolerable salts with usual carrier and optionally additional and / or Excipients in or a suitable dosage form brings.

The medicaments according to the invention can be used in the Production of the aforementioned galenic forms of preparation  also together with other suitable active ingredients, for example antithrombotics, antihyperlipidemics, Analgesics, sedatives, antidepressants, antianginal Agents, cardiotonics, antiarrhythmics, diuretics, Antihypertensives including β-receptor and Calcium blockers, plasma expanders and others Vasotherapeutic agents.

Finally, some preliminary or intermediate products are also available Preparation of the compounds of formula I new and therefore also subject of the invention: it is the links 1-methyl, 1,2-dimethyl and 1-ethyl-4-imidazole sulfonic acid chloride.

These connections are advantageously made by that he

• a) 1-methyl or 1,2-dimethyl or 1-ethyl imidazole with Chlorosulfonic acid ClSO₃H, optionally under subsequent addition of SOCl₂, causes the reaction, or that one
• b) 1-methyl- or 1,2-dimethyl- or 1-ethyl-4-mercapto- imidazole with Cl₂ oxidizing chlorinated.

More detailed explanation of the two process variants:

• a) The reaction with chlorosulfonic acid is advantageously carried out at elevated temperature, preferably between about 130 ° C. and 160 ° C., if possible without suctioning off the hydrogen chloride formed.
  Any subsequent thionyl chloride addition is carried out at slightly elevated temperatures, preferably between about 60 and 80 ° C., for better reaction control, at which the reaction mixture has become readily stirrable and rapid reaction of the thionyl chloride is ensured. By pouring the reaction mixture onto an ice-water mixture, it is possible for these imidazole derivatives to separate almost pure 1-alkyl-4-imidazolesulfonic acid chlorides, while the 5-imidazolesulfonic acid chlorides formed remain predominantly in solution and hydrolyze to sulfonic acids. In order to avoid losses due to hydrolysis of the 4-imidazole sulfonic acid chlorides as well, rapid drying is recommended, preferably in solvents such as dichloromethane, with drying agents such as sodium sulfate.
• b) 2-Mercaptoimidazole can according to literature Methods with chlorine, if possible in stoichiometric Application, oxidized to the 2-imidazole sulfonyl chlorides become [R. G. Jones et al., J. Am. Chem. Soc. 71, 4000 (1949)]. The conditions for chlorine oxidation 1-Alkyl- and 1,2-dialkyl-4-mercaptoimidazoles are similar (at about -10 to + 10 ° C in dilute Hydrochloric acid.

The following (production) examples are intended to be closer Explanation of the invention serve.

The structures of all the compounds described below were by elemental analysis and IR and 1 N NMR spectra secured. In the following, this is the vacuum Water jet pump understood. To Thin layer chromatography became silica gel plates (Silica gel 60F₂₅₄ special 0.25 mm, Riedel-de Haen AG, D-3016 Seelze) used.

The indicated yields are not optimized.  

Then follows the manufacturing examples pharmacological part, from which the effectiveness of compounds according to the invention emerges; the pharmacological part also contains comparative values the standard therapeutic pentoxyfylline (= 1- (5-oxohexyl) - 3,7-dimethyl-xanthine).

(Manufacturing) examples A) Compounds of formula I with X = OH Example 1 5-chloro-1-methyl-4-imidazole sulfonic acid

33 g (0.28 mol) of 5-chloro-1-methylimidazole are heated in 160 ml of fuming sulfuric acid at 160-180 ° C for 4 hours. After cooling, the reaction mixture is carefully poured onto ice. The product crystallizes out of the cold aqueous solution (about 1.5 l). After recrystallization from water twice, the title compound is obtained in the form of coarse yellowish crystals with a melting point of 309-310 ° C.
Yield: 34 g (46.9% of theory).

Example 2 1-ethyl-4-imidazole sulfonic acid

5.6 g (29 mmol) of 1-ethyl-4-imidazolesulfonic acid chloride from Example C-2 are suspended in 70 ml of water at room temperature until a clear solution has formed. After evaporation in vacuo, the residue is recrystallized from ethanol / water to give the title compound, melting point 278 ° C.
Yield: 5 g (99% of theory)

Example 3 1-methyl-4-imidazole sulfonic acid

An analogous manner to that described in Example 2 is obtained from 1-methyl-4-imidazolesulfonic acid chloride from example C-1 in about 70% yield the title compound with the Melting point 288-289 ° C, after recrystallization Ethanol / methanol.

Example 4 1-methyl-2-imidazole sulfonic acid

In an analogous manner to that described in Example 2, one obtains from 1-methyl-2-imidazole sulfonic acid chloride [R. O. Roblin, Jr. and J. W. Clapp J. Am. Chem. Soc. 72, 4890 (1950)] approximately 72% yield of the title compound with the melting point 234-236 ° C, after recrystallization from ethanol / methanol.

Example 5 4-chloro-1-methyl-5-imidazole sulfonic acid

In an analogous manner to that described in Example 2, one obtains from 4-chloro-1-methyl-5-imidazolesulfonic acid chloride [M. H. Fisher, W.H. Nicholson and R.S. Stuart, Can. J. Chem. 39, 1336 (1961)] in about 39% yield the title compound with the melting point 260-261 ° C.

Example 6 1-methyl-5-imidazole sulfonic acid

A solution of 3.1 g (17 mmol) of 1-methyl-4-chloro-5-imidazolesulfonic acid from Example 5 in 100 ml of water is in the presence of 0.5 g of Pd / C catalyst with shaking at an initial pressure of 3. 45 bar hydrogen hydrogenated at 25 ° C to constant pressure. The crystalline residue remaining after filtering off the catalyst and evaporating the water in vacuo is recrystallized from ethanol to give the title compound with a melting point of 286-287 ° C.
Yield: 1.5 g (58.5% of theory)

Example 7 N- (3-morpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide (Hydrochloride)

To a solution of 24 ml (0.17 mol) of 3-morpholinopropylamine-1 in 50 ml of acetonitrile (or dichloromethane) is added dropwise Solution of 30 g (0.17 mol) of 1-methylimidazole-4-sulfonic acid chloride from Example C-1 in 150 ml acetonitrile. By external Cooling with ice water will reduce the temperature of the Reaction mixture at room temperature or below held. The mixture is stirred at room temperature for 6 h. The precipitate is filtered off and from Acetonitrile recrystallized to 46 g (85% of theory) of Title compound (hydrochloride) of mp. 207-208 ° C to surrender.

The hydrochloride is formed in to form the free base Dichloromethane suspended and with the equivalent amount a 1 N K₂CO₃ solution shaken. The one after Separation from the aqueous phase, drying and removal The residue remaining in the vacuum is removed Recrystallized acetonitrile. The free base then shows a melting point of 138-139 ° C.  

Example 8 N- (3-morpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide

16.7 g (46.5 mmol) of 5-chloro-N- (3-morpholino-1-propyl) -1-methyl-4-imidazolesulfonamide hydrochloride from Example 32 in 2503 in the presence of 3 g of Pd / C catalyst ml of water at 25 ° C and 3.45 bar hydrogenated. The residue which remains after filtration and evaporation in vacuo is converted into the free base with saturated potash solution, extracted with dichloromethane and recrystallized from dioxane / diisopropyl ether to give the crystalline title compound, identical to that according to Example 7.
Yield: 6.3 g (43% of theory)

Analogously to Example 7, 1-methyl-4-imidazolesulfonic acid chloride and the amine of rows b give the respective title compound of rows a:

Example 27 N- [3- (4-methylpiperazino) propyl] -1-methyl-4-imidazolesulfonamide - Dihydrogen fumarate

An analogous manner to that described in Example 7 is obtained from 1-methyl-4-imidazolesulfonic acid chloride and 3- (4- Methylpiperazino) propylamine the free base of the Title link. That after adding an ethanolic double molar amount of fumaric acid in about 42% yield Crystallizing dihydrogen fumarate melts at 209-210 ° C.

Example 28 N- [3- (N-benzyl-N-methylamino) -1-propyl] -1-methyl-4- imidazole sulfonic acid amide hydrogen fumarate

In an analogous manner to that described in Example 7, the free base of the title compound is obtained from 1-methyl-4-imidazolesulfonic acid chloride and 3- (N-benzyl-N-methylamino) -1-propylamine. The hydrogen fumarate which crystallizes after the addition of an ethanolic equimolar amount of fumaric acid melts at 184-185 ° C.
Yield: 53.4% of theory. Th.

An analogous manner to that described in Example 7 is obtained

29) N- (3-morpholinopropyl) -1-methyl-2-imidazolesulfonic acid amide Hydrochloride, mp. 177-178 ° C (from ethanol) from 1- Methyl-2-imidazole sulfonic acid chloride and 3-morpholinopropylamine.

30) N- (2-morpholinoethyl) -1-methyl-2-imidazolesulfonic acid amide Hydrochloride, mp 197-198 ° C (from ethanol) from 1- Methyl-2-imidazole sulfonic acid chloride and 2-morpholinoethylamine.

31) N- (3-morpholinopropyl) -4-chloro-1-methyl-5-imidazolesulfonamide, Mp 113-114 ° C (from ethanol) 4-chloro-1-methyl-5-imidazolesulfonic acid chloride and 3- Morpholinopropylamine.

32) N- (3-morpholinopropyl) -5-chloro-1-methyl-4-imidazolesulfonic acid amide Hydrochloride, mp. 179-180 ° C (from Methanol / isopropanol) from 5-chloro-1-methyl-4-imidazolesulfonic acid chloride and 3-morpholinopropylamine.

33) N- (3-morpholinopropyl) -1,2-dimethyl-4-imidazolesulfonic acid amide Hydrochloride, mp. 181-182 ° C (from ethanol) from 1,2-dimethyl-4-imidazolesulfonic acid chloride and 3- Morpholinopropylamine.

34) N- (5-morpholino-1-pentyl) -5-chloro-1-methyl-4-imidazolesulfonamide - Hydrochloride, mp. 218-219 ° C (from Ethanol) from 5-chloro-1-methyl-4-imidazolesulfonic acid chloride and 5-morpholinopentylamine.

35) N- (3-morpholinopropyl) -1-propyl-4-imidazolesulfonic acid amide and N- (3-morpholinopropyl) -1-propyl-5-imidazolesulfonic acid amide as a 4,5-position isomer mixture obtained from the mixture of isomers of 1-propyl-4- and 1-Propyl-5-imidazole sulfonic acid chlorides from Example C-4  and N- (3-aminopropyl) morpholine in the ratio 20.4: 79.5%. This mixture is by HPLC on modified silica gel (RP 18, Merck) using a mixture of Water: acetic acid: acetonitrile (7.5: 1.5: 1) separately elute.

36) N- (3-morpholino) -1-n-butyl-4-imidazolesulfonic acid amide and N- (3-morpholinopropyl) -1-n-butyl-5- imidazolesulfonic acid amide as a 4,5-position isomer mixture to be obtained from the isomer mixture of 1-butyl-4- and 1-butyl-5-imidazolesulfonic acid chlorides from Example C-5 and N- (3-aminopropyl) morpholine in the ratio 68.1%: 17.5%. This mixture is by HPLC on modified silica gel (RP 18, Merck) using a mixture of Water: acetic acid: acetonitrile (7.5: 1.5: 1) separately elute.

Example 37 N- (3-morpholinopropyl) -1-ethyl-4-imidazolesulfonic acid amide Hydrogen fumarate

Analogously to Example 7, 10 g (51 mmol) of 1-ethyl-4-imidazole sulfonic acid chloride from example C-2 with 7.5 ml (51 mmol) 3-morpholinopropylamine reacted in 200 ml of acetonitrile and processed accordingly. The hydrochloride thus obtained is dissolved in methanol, and by an equivalent amount methanolic sodium methylate solution in the free base transferred. The oil remaining in the vacuum after evaporation crystallizes after addition of an ethanolic equimolar Amount of fumaric acid as a hydrogen fumarate with melting point 148 -149 ° C.  

Example 38 N- (1,3-Dimorpholino-2-propyl) -1-methyl-4-imidazole sulfonamide

4 g (17.5 mmol) of 1,3-dimorpholino-2-propylamine and 3.5 g (17.5 mmol) of MSTFA [N-methyl-N- (trimethylsilyl) trifluoroacetamide] are combined under argon and for 17 hours at room temperature touched. The clear solution is then concentrated in vacuo at 40 ° C./0.1 Torr. A solution of 3.16 g (17.5 mmol) of 1-methyl-4-imidazolesulfonic acid chloride in 20 ml of absolute dichloromethane is added to the resulting oil at 20 ° C. with stirring. After stirring for a further 6 hours at 20 ° C., the solvent is distilled off in vacuo at 20 ° C./18 torr. The remaining oil crystallizes from isopropanol. After decolorization with activated carbon, recrystallization from methanol / isopropanol gives the title compound with the melting point 191-192 ° C.
Yield: 3.9 g (60% of theory)

Example 39 N- (3-N-ethyl-N-isopropylaminopropyl) -1-methyl-4-imidazolesulfonic acid amide

The solution of 10.8 g (0.06 mol) of 1-methyl is added to a solution of 13 g (0.06 mol) of 1-trimethylsilylamino-N-ethyl-N-isopropyl-3-propylamine in 100 ml of acetonitrile at room temperature -4- imidazolesulfonic acid chloride from Example C-1 was added dropwise and stirring was continued for 6 hours. The residue remaining after evaporation in vacuo is recrystallized from isopropanol to give the title compound with a melting point of 145-146 ° C.
Yield: 5.7 g (29.2% of theory)

Example 40 N- [4- (4-hydroxyphenyl) piperazino] -5-chloro-1-methyl-4- imidazole sulfonic acid amide

A solution of 20 g (93 mmol) of 5-chloro-1-methyl-4-imidazolesulfonic acid chloride in 250 ml of chloroform is added dropwise to 16 g (90 mmol) of 4- (4-hydroxyphenyl) piperazine in 250 ml of chloroform at room temperature. Then 41 ml (0.3 mol) of triethylamine are slowly added dropwise. If, after stirring for 6 hours at room temperature, there is no longer any acid chloride by thin layer chromatography, the precipitate formed is filtered off, washed several times with water, dried and recrystallized from acetonitrile. The title compound melts at 249-250 ° C.
Yield: 22 g (66.3% of theory)

Example 41 1- (1-methyl-5-chloro-4-imidazolesulfonyl) -4- [4- (1-methyl-5- chlor-4-imidazolesulfonyloxy) phenyl] piperazine

The mother liquors from Example 40 are evaporated in vacuo. The residue is washed with water and recrystallized from water / ethanol. The title compound thus obtained melts at 196-197 ° C.
Yield: 3.5 g (21.1% of theory)

Example 42 4- (1-methyl-4-imidazolesulfonyl) tetrahydro-4H-1,4-thiazine

2 g (11 mmol) of 1-methyl-4-imidazolesulfonic acid chloride from Example C-1, dissolved in 20 ml of acetonitrile, are added dropwise to a solution of 1.51 ml (15 mmol) of thiomorpholine in 50 ml of acetonitrile with stirring at room temperature. The reaction mixture is stirred for 6 hours, filtered and evaporated in vacuo. The remaining residue is recrystallized from isopropanol to give the title compound, melting point 154-155 ° C.
Yield: 1.37 g (50% of theory)

In an analogous manner to that described in Example 42 one:

Example 50 N- (3-propargyl) -1-methyl-4-imidazolesulfonic acid amide

A solution of 3 g (16.6 mmol) of 1-methyl-4 is added to a solution of 1.14 ml (16.6 mmol) of propargylamine in 30 ml of dichloromethane, cooled to -20 ° C., with further cooling and with stirring imidazolesulfonic acid chloride from Example C-1 added dropwise in 40 ml of dichloromethane. The reaction solution is then allowed to warm up slowly to room temperature. The precipitate is filtered off and recrystallized from isopropanol to form the title compound of melting point 145 ° C.
Yield: 1.5 g (45.3% of theory)

Example 51 4- [2- (1-methyl-4-imidazolesulfonyl) aminoethyl] phenoxyacetic acid

6.3 g (32 mmol) of 4- (2-aminoethyl) phenoxyacetic acid are added to a solution of 9.7 g (79 mmol) of potassium carbonate in 50 ml of water and stirred for 5 minutes. A suspension of 5.8 g (32 mmol) of 1-methyl-4-imidazolesulfonic acid chloride from Example C-1 in 20 ml of water is slowly added to this suspension. It is heated to 80 ° C. and stirred at this temperature for 2 hours. After cooling to room temperature, the reaction solution is acidified to pH 4 with 2 N hydrochloric acid. The precipitate is separated off, washed several times with water and recrystallized from dilute acetic acid to give the title compound with a melting point of 203-204 ° C.
Yield: 6 g (55.2% of theory)

Example 52 4- [2- (5-chloro-1-methyl-4-imidazolesulfonyl) aminoethyl] - phenoxyacetic acid

An analogous manner to that described in Example 51 is obtained the title compound in 29% yield 5-chloro-1-methyl-4-imidazolesulfonic acid chloride and 4- (2-aminoethyl) phenoxyacetic acid. The water recrystallized compound melts at 174-175 ° C.  

Example 53 N- (3-morpholino-1-propyl) -1-methyl-5-imidazole sulfonamide Hydrochloride

1 g (2.8 mmol) N- (3-morpholinopropyl) -4-chloro-1-methyl- 5-imidazole sulfonamide from Example 31 is in 130 ml of 25% aqueous ethanol dissolved with 0.3 g Pd / C catalyst offset and with shaking at an initial pressure of 3.45 bar hydrogenated until the end of the hydrogen uptake. The The catalyst is filtered off. The filtrate is in a vacuum concentrated and the residue recrystallized from ethanol. The title compound with the melting point 205- 206 ° C in a yield of 0.8 g (88% of theory).

Example 54 1,6-bis (1-methyl-4-imidazolesulfonamido) hexane

13 g (27 mmol) of 1,6-bis (5-chloro-1-methyl-4-imidazolesulfonamido) hexane from Example 47 are in 250 ml of 1 N sodium hydroxide solution over 3 g of 10% Pd / C catalyst with shaking hydrogenated at an initial pressure of 3.45 bar until the end of the hydrogen uptake. After the catalyst has been separated off, the filtrate is evaporated in vacuo. The residue was recrystallized from water / methanol to give the title compound as colorless crystals with a melting point of 153-154 ° C.
Yield: 6.1 g (55% of theory)

Example 55 N- [3- (1-Piperazinyl) propyl] -1-methyl-4-imidazole sulfonamide Hydrochloride

3 g (7.2 mmol) of N- [3- (4-benzyl-1-piperazinyl) -1-propyl] -1-methyl-4-imidazolesulfonamide hydrochloride from Example 26 are in a solution of 30 ml of ethanol in 150 ml Hydrogenated 25% ammonium hydroxide solution with shaking, at an initial pressure of 3.45 bar and room temperature until hydrogen uptake ceased in the presence of 1 g of Pd / C catalyst. After concentration under reduced pressure, the residue is recrystallized from ethanol to give the desired compound with a melting point of 174-175 ° C.
Yield: 1.4 g (59% of theory)

Example 56 4-methyl-4- [3- (1-methyl-4-imidazolesulfamoyl) -1-propyl] - morpholinium iodide

2 g (6.9 mmol) of N- (3-morpholinopropyl) -1-methyl-4-imidazole sulfonamide from Example 7 are at room temperature in a solution of 0.48 ml (7.6 mmol) of iodomethane in 50 ml of acetonitrile for 8 hours touched. The precipitate formed is separated, washed well with acetonitrile and dried to give the title compound with a melting point of 204-205 ° C.
Yield: 2.5 g (84% of theory)

Example 57 4- (1-methyl-4-imidazolesulfonyl) tetrahydro-4H-1,4-thiazine 1,1-dioxide

1 g (4 mmol) of 4- (1-methyl-4-imidazolesulfonyl) tetrahydro-4H-1,4-thiazine from Example 42 are taken up in 10 ml of chloroform and added dropwise at 0-5 ° C. with a solution of 1. 39 g (8 mmol) of m-chloroperoxybenzoic acid were added. After warming to room temperature, stirring is continued for 2 hours, during which the reaction product precipitates, which is filtered off with suction and recrystallized from water. The title compound thus obtained melts at 179-180 ° C.
Yield: 0.3 g (26.6% of theory)

Example 58 4- [4- (5-chloro-1-methyl-4-imidazolesulfonyl) piperazinyl] - phenoxyacetic acid ethyl ester

2 g (5.6 mmol) of N- [4- (4-hydroxyphenyl) piperazino] -5-chloro-1-methyl-4-imidazolesulfonamide from Example 40 are taken up in 70 ml of ethanol, with 0.22 g (5 , 5 mmol) of sodium hydroxide, stirred for 30 minutes, and 0.86 g (6 mmol) of ethyl bromoacetate were added dropwise. If after 6 hours of stirring at room temperature the reaction by TLC is still incomplete, 0.42 g (2.5 mmol) of ethyl bromoacetate and 0.12 g (3 mmol) of sodium hydroxide are added, the mixture is heated to 50 ° C. and stirred for about 10 hours to. After evaporation in vacuo, the residue is taken up in dichloromethane and washed with 2 N NaOH. After drying over sodium sulfate, the organic phase is evaporated in vacuo. The crystalline residue can be recrystallized from isopropanol. The title compound thus obtained melts at 148-149 ° C.
Yield: 0.8 g (32% of theory)

Example 59 N- (6-aminohexyl) -1-methyl-4-imidazolesulfonic acid amide Dihydrochloride

2.6 g (10 mmol) of N- (5-cyanopentylamino) -1-methyl-4-imidazolesulfonamide from Example 49 are dissolved in 50 ml of about 5 N ethanolic ammonia solution, mixed with 1 g of Raney nickel and with shaking an initial pressure of 3.45 bar hydrogenated until the end of the hydrogen uptake. The catalyst is filtered off. The filtrate is concentrated in vacuo. The remaining oil is dissolved in absolute ethanol. When ethanolic hydrochloric acid is added, the title compound precipitates as a crystalline salt which, after separation and drying, has a melting point of 215-223 ° C.
Yield: 2.3 g (69% of theory)

Example 60 N- (3-aminopropyl) -1-methyl-4-imidazolesulfonic acid amide Hydrochloride

An analogous manner to that described in Example 59 is obtained the title compound from N- (3-cyanoethylamino) -1-methyl-4- imidazolesulfonic acid amide from Example 48 with the melting point 168-169 ° C in about 55% yield.

Example 61 N- (3-thiomorpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide S-oxide hydrochloride

A solution of 3.5 g (10 mmol) of N- (3-thiomorpholinopropyl) -1-methyl-4-imidazolesulfonamide hydrochloride from Example 13 in 30 ml of 50% strength aqueous methanol is converted to a solution of 1 at -5 ° C. 9 g (9 mmol) of sodium iodate in 25 ml of water were added dropwise. A precipitate that has formed in the meantime goes back into solution after a further 20 minutes. After standing overnight, the reaction solution is mixed with excess sodium bicarbonate, evaporated to dryness in vacuo and purified by column chromatography on silica gel with dichloromethane: methanol 9: 1 to 0: 10. The eluted oil is converted into the hydrochloride using ethanolic hydrochloric acid and the title compound thus obtained is recrystallized from ethanol / methanol to the melting point of 186 ° C.
Yield: 1.2 g (32% of theory)

Example 62 N- (3-methylamino-1-propyl) -1-methyl-4-imidazole sulfonamide Hydrochloride

15 g (41.7 mmol) of N- [3- (N-benzyl-N-methylamino) -1-propyl] -1-methyl-4-imidazolesulfonamide hydrochloride from Example 28 are in a solution of 100 ml of 25% ammonia solution and hydrogenated 100 ml of ethanol in the presence of 2 g of 10% Pd / C catalyst. After the hydrogen uptake has ended and the catalyst has been filtered off, the filtrate is evaporated in vacuo. The residue is recrystallized from ethanol to give the title compound, melting point 169-170 ° C.
Yield: 2.3 g (20.5% of theory)

C) Intermediates (imidazole sulfonic acid chlorides) Example 1 1-methyl-4-imidazole sulfonic acid chloride

1-Methylimidazole (250 g, 3.05 mol) becomes like this Chlorosulfuric acid (600 ml, 9.03 mol) dropwise admitted that an internal temperature of 30 ° C does not is exceeded without the hydrogen chloride formed suck off. When the addition is complete, the reaction mixture Stirred at 150 ° C for 6 h. At 60 ° C with thionyl chloride (340 ml, 4.66 mol) were added and then 6 h at 100 ° C. Bath temperature heated. After cooling to room temperature the viscous reaction mixture on so much ice poured that about 7.5 l of water-ice mixture remains at the end. The precipitate is filtered off and briefly sucked dry. Then either in a thin layer dried in a vacuum drying cabinet at 50 ° C and 15 Torr, or it is preferably taken up with dichloromethane Dried sodium sulfate and the solvent in vacuo exempted. Yield: 176 g (32% of theory) became colorless  Obtain crystals (mp: 89-90 ° C). To remove the isomeric 5-imidazole sulfonic acid formed as a by-product the mother liquor is largely converted into Rotary evaporator concentrated at 15 torr in vacuo. At Addition of ethanol crystallizes Imidazole sulfonic acid mixture from that of ethanol can be recrystallized.

Example 2 1-ethyl-4-imidazole sulfonic acid chloride

In an analogous manner as described in Example C-1 the title compound in about 24.7% yield with the Melting point 34-35 ° C from 1-ethylimidazole Chlorosulfonic acid and thionyl chloride.

Example 3 1,2-dimethyl-4-imidazole sulfonic acid chloride

In an analogous manner as described in Example C-1 the title compound is obtained in 30% yield 1,2-dimethylimidazole using chlorosulfonic acid and Thionyl chloride. It can be made from toluene / cyclohexane recrystallize and then has a melting point of 90- 91 ° C.

Example 4 1-propyl-4-imidazole sulfonic acid chloride and 1-propyl-5- imidazole sulfonic acid chloride

In an analogous manner as described in Example C-1 a mixture of the Title compounds from 1-propylimidazole using Chlorosulfonic acid and thionyl chloride, which is conveniently in Form of their derivatives is separated.  

Example 5 1-butyl-4-imidazole sulfonic acid chloride and 1-butyl-5- imidazole sulfonic acid chloride

In an analogous manner as described in Example C-1 a mixture of the in about 17% yield Title compounds from 1-butylimidazole using Chlorosulfonic acid and thionyl chloride, which is conveniently in Form of their derivatives is separated.

The compounds of the formula I according to the examples from sections A and B are compiled in Table 1 below; if the salts were prepared in the examples, this is also taken into account in the table. The table also shows the process variants according to which the compounds in the examples in question were prepared.

Pharmacological testing and results 1) Effect on contractility of skeletal muscle after chronic ischemia

In the past few years has been in the imaginations on the pathophysiology of chronic peripheral arterial occlusive disease a remarkable change accomplished when the scientific interest in increasingly from macro circulation to Microcirculation shifted. Disorders in the Microcirculation therefore manifests itself in an undersupply of substrates with it resulting tissue ischemia, which in turn leads to a Impairment of the function of the affected Limb leads. The logical consequence of this is that the target organ skeletal muscle more and more in the Foreground moves. That means that therapeutic goal of any drug Therapy the improvement or - ideally - the Restore normal performance got to. The clinical effectiveness will also consequently on people with the help of pain-free Walking distance determined on the treadmill.

Testing the compounds of the invention for their Function-improving effect was therefore carried out based on measurements of the contraction force in ischemic Skeletal muscle with the experimental setup described below, the standard therapeutic pentoxifylline as Comparative drug was included in the studies (see also Okyayuz-Baklouti, I., in: Muscle Ischaemia, Functional and Metabolic Aspects, eds I. Okyayuz-Baklouti and O. Hudlicka, Dr. C. Wolf and Son, Munich, p 103-126, 1988; Okyayuz-Baklouti, I., European J. of Pharmacology 166: 75-86, 1989).  

Male Wistar rats with one served as experimental animals Body weight from 380 to 410 g. In hexobarbital anesthesia (®Evipan sodium, 200 mg / kg body weight (= body weight) i.p.) the animals became a one-sided ligature of the right Femoral artery set in the groin. After sprinkling Penicillin sulfonamide powder for antibiotic The small surgical wound was closed and the animals became constant until fully awakened observed. The substance application started a week later by oral administration with a gavage (6 mg / kg body weight, Carboxymethyl cellulose sodium suspension) and was used for 7 Days continued (once a day, approx. 7.30 to 8.30). The contraction force was 24 hours after the last one Substance measured to exclude acute effects, and according to the following test protocol:

The animals were treated with ®Nembutal (pentobarbital sodium, 35 mg / kg body weight i. p.) anesthetized the muscles of the affected Extremity exposed (Gastrocnemius Plantarius Soleus Group) and the tendon was attached to a force transducer (Rhema Z6, company Rhema, Hofheim) with a preload of 50 g tied up. A super fusion with physiological Saline (37 ° C) was used to prevent dehydration and cooling. The mean arterial blood pressure was via Statham (= blood pressure monitor) via a cannulated Carotid artery continuously to control the physiological status of the animals during the experiment recorded. All animals breathed spontaneously through one inserted tracheal tube.

After these preparations, the muscle was replaced by direct electrical stimulation (2.5 mA, 2 Hz) for contraction brought (stimulator I, Hugo Sachs, Federal Republic Germany). As a measurement parameter for the effect of the preparation served the absolute contraction force in grams different times of stimulation. The initial Contractility of the chronic ischemic skeletal muscle  differs only insignificantly (spread of the Attempts) of that of the normal muscle. But since the underserved muscle tired faster, the falls Contraction force during the selected here Pacing interval of 5 minutes significantly faster and more than normal non-ischemic muscle. If one now the maximum contraction force at the beginning of the Stimulation by the remaining power after 5 minutes dividing tiring stimulation, one can Calculate index EI "for the muscle in question; the greater the numerical EI, the greater the fatigue. So for normal, the EI only moves with the vehicle treated muscle between 1.78 and 3.29 (see Table 2). The fatigue of the ischemic muscle is over 40 to 60% higher.

In Table 2 the EI of the normal muscle was compared with the EI of the compared to ischemic treated muscle because this is on clearest a possible improvement of the function in Towards normalization. This means that ever is less than the numerical value of the percentage change, the more effective the particular preparation, i.e. H. a percentage change with z. B. means negative sign even lower fatigue compared to non-ischemic untreated muscle. For each Test preparation, 4 to 6 individual tests were carried out.

2) Antithrombotic activity

An important factor in the genesis and course of peripheral arterial disease and others for indications used in this group of substances thrombotic events. So the invention Compounds on inhibition of laser-induced thrombosis tested (see: Seiffge, D. and Kremer, E., Thromb. Res. 42, 331-341, 1986):  

These investigations were carried out on female Sprague-Dawley Rats with a body weight of approx. 200 g. The animals were with 0.1 mg of atropine sulfate s. c. premedicated and with 100 mg ketamine hydrochloride and 4 mg xylazine per kg body weight i. p. anesthetized. Arterioles and Venoles of the layer covered with degassed paraffin oil Mesentery with a diameter of approx. 13 µm. The beam of the 4 W argon laser (company Spectra-Physics, Darmstadt) using a beam adaptation and adjustment system coaxial in the inverted beam path of a microscope (ICM 405, LD ®Epiplan 40 / o. 60, Zeiss, Oberkochen). The one used Wavelength was 514.5 nm with a power above the 30 mW lens. The exposure time per single shot lasted 1/15 sec. All measurements were done by video camera (®Trinicon tube, Sony, Cologne) and recorded on one Recorder (®Sony U-matics 3/4 ″) saved. The test substances The animals were administered orally in various doses 1 Hour at i. v. Administered 10 minutes before the start of the experiment; Control animals received the same amount of placebo. The The substances were administered as a single dose once on Day or once a day for several days. For evaluation counted the number of laser shots needed to get one wall thrombosis of a minimum size of half To produce vessel diameter. This means the bigger the Number of laser shots the more effective the preparations are in this test. Table 3 shows the percentage inhibition of Thrombosis indicated.

3) Acute toxicity

The LD50 ranges were determined in accordance with the standard about that within 7 days in NMRI mice single intravenous (IV) or intraperitoneal (IV) Administration of mortality (NMRI = NIH Medical Research Institutes). The values are also in Table 3 summarized.  

4) Additional special tests

The clear superiority of the invention Connections especially compared to the most common Therapy of peripheral circulatory disorders therapeutic used preparation, the pentoxifylline, could also in impressively confirm further special tests.

An important advantage of the substances according to the invention an example of the compound from example 7 is that it thrombosis in hyperlipidemic, spontaneously hypertensive and thus rats prone to stroke and in Inhibit atherosclerotic rabbits. So the substance inhibits from Example 1 the laser-induced thrombosis daily administration of 10 or 30 mg / kg for 7 days in hyperlipidemic hypertensive rats by 18 or 32% and in atherosclerotic rabbits after daily administration from 30 mg / kg for 14 days by 36%.

Furthermore, the substances according to the invention not only inhibit the laser-induced thrombus formation, but beyond inhibit them, especially the substance from Example 7, also photochemically induced thrombosis. In this model Anesthetize rats as described in 2) above. The Investigations were carried out on mesenteric arterioles with a Diameters from 11 to 50 µm. The induction of thrombosis was modified in accordance with a literature Method carried out (Herrmann, K.H., Microvasc. Res. 26, 238 -249, 1983) and is based on photochemical release of singlet oxygen, which is local to the endothelial lesion leads. The animals to be examined received an intravenous one Injection of 0.3 ml of a 10% solution of fluorescein isothiocyanate Dextran 70 (FITC-Dextran 70 s, Sigma company, Munich). The arteriole was examined under the microscope and centered in the observation field. After that the FITC Dextran in the blood vessel with a special lamp and  Filter device excited (excitation 490 nm, emission 510 nm). It was time to evaluate the thrombus formation taken from the time of the suggestion to the The formation of a first wall thrombus passes. In 5 vessels were examined in this way for each animal. It it turned out that the thrombosis by the Compound from Example 7 dose-dependently and statistically was significantly inhibited (1, 3, 10 mg / kg p.o .: 69, 75, 130%). In comparison, pentoxifylline did only one Inhibition of 29, 18, 68% at 1, 3 and 10 mg / kg p. o. After i. v. Administration of the compound from Example 7 of 3 or 10 mg / kg the thrombosis was inhibited by 36% and 56%; at i. v. Administration of 3 or 10 mg / kg of pentoxifylline by 3% or 38%.

With the help of laser Doppler flowmetry (LDF) can on non-invasive and continuous way of erythrocyte flux (Number of cells flowing under the laser beam x their speed) in the capillary bed of the skeletal muscle Rat measured (Perimed laser Doppler flow meter PF2, company Perimed, Sweden). This technique does exist, however not absolute blood flow values, but qualitative ones Changes in volts, but the signal obtained is linear correlated with the flux. The device was as follows set: 12 kHz, gain 10, time constant 1.5 sec, 37 ° C. Male Wistar rats weighing 380- The right femoral artery was exposed and over 430 g a small muscle area (tibialis anterior) the skin and dissected the connective tissue. About 1 mm above this area the probe was placed. As soon as the curve stabilizes the femoral artery was clamped occluded, whereupon the LD curve in that of this vessel supplied muscle quickly fell off, then as a result of spontaneous Opening of collateral vessels rose slightly again and finally settling on one from baseline level decreased considerably (residual blood flow in the  acute ischemic muscle approx. 25%). At that time the test substances were infused intravenously in aqueous solution (0.03 and 0.6 mg / kg / min). As a measurement parameter for the The maximum percentage increase in Erythrocyte fluxes after substance administration during occlusion (see also Okyayuz-Baklouti, I., European J. of Pharmacology, 166: 75-86, 1989). It turned out out that blood circulation in the microcirculation for example after infusion of the compound from example 7 strong and dose-dependent increase (+ 53.3% in the low and + 80.6% in the higher dosage). In comparison pentoxifylline caused a 24.6% increase in low and by 33.1% in the higher dosage. Per The preparation and dose were used in 3-7 animals.

The contractility on the acute ischemic muscle was in one similar experimental setup as described under 1), measured. The muscle, which was initially normally supplied with blood, was through direct electrical stimulation (1.2 Hz, 2.5 mA) for brought isometric contraction. Then the right one Femoral artery occluded for 5 min using a clamp. The Contraction force falls due to the insufficient Substrate supply significantly decreased (vehicle infusion). The jar was then reopened and the Initial contractility was observed before the first occlusion reached. During the second occlusion that followed the preparations to be tested intravenously in aqueous solution the jugular vein is applied. For each preparation and dose, 4- 8 animals used. The decrease in contractile force during the occlusion with and without substance administration was compared and the percent change was used to assess the substance effect used. They also fell in this test Substances according to the invention exemplify the compound  from Example 7 by excellent effects. It was like that Contractile force after a dose of 0.03 mg / kg / min + 17.2%, and after a dose of 0.3 mg / kg / min by + 25.2% improved while pentoxifylline also in this Function test showed only marginal effect.

The compounds according to the invention show excellent results Effects on the performance of the ischemic muscle both during chronic and during acute Lack of blood circulation, as well as beneficial effects on the capillary Flow paired with an excellent inhibition of the intravascular thrombosis.  

Table 2

Fatigue Index (EI) Rat skeletal muscle

For all preparations 6 mg / kg p. o. over 7 days, n = 4-6.  

Table 3

Inhibition of laser-induced thrombosis in rat mesenteric arterioles and toxicity

Claims (13)

1. Imidazole compounds of the formula I. in which
R¹ = (C₁-C₆) alkyl,
R², R³ = identical or different and each = H, halogen (F, Cl, Br, J), preferably Cl, or (C₁-C₃) alkyl,
X = OH or an amino group of the formula II wherein
R⁴ = H or (C₁-C₇) -, preferably (C₁-C₄) alkyl, optionally substituted with CN, NH₂ or COOH
R⁵ = (C₁-C₈) -, preferably (C₁-C₅) -alkyl radical, in which - if it has more than 1 carbon atom - a phenylene radical can also be between 2 carbon atoms and whose (aliphatic) carbon atoms are substituted are with 1 or more of the following groups: OH,
(C₁-C₃) alkoxy,
Phenyl, optionally substituted with 1-3 OH, (C₁-C₃) alkyl groups, (C₁-C₃) alkoxy-COOH, and / or (C₁-C₃) alkoxy- (C₁-C₄) alkyl,
COOH,
COO (C₁-C₃) alkyl,
CONH₂,
CN,
(C₂-C₅) alkynyl,
NH₂,
NHR⁶
N (R⁶) ₂
N⊕ (R⁶) ₃
wherein R⁶ is the same or different radicals of the type (C₁-C₄) alkyl,
(C₂-C₆) alkoxyalkyl and phenylalkyl with 1-3 C atoms in the alkyl part,
NH-CO- (C₁-C₆) alkyl, (Meaning of R¹, R² and R³ as above),
monocyclic 5- to 7-membered saturated or unsaturated - preferably saturated - heterocyclic radicals with 1 N atom and optionally also an additional N, O or S atom in the ring, optionally substituted with (C₁-C₃) alkyl, phenyl, phenylalkyl with 1-3 C atoms in the alkyl part, OH, and / or oxo (= O), including the open and cyclic ketal forms with 2-6 C atoms in the ketal part, and in which the ring S atom - if present - also can be oxidized to sulfoxide (SO) - or sulfone (SO₂) form or in which R⁴ and R⁵ together with the amide N atom to which they are attached form a - preferably saturated - 5- to 7-membered heterocyclic ring which in addition to the amide-N, a further heteroatom from the group N, O and S can contain in the ring, although the unsubstituted morpholine ring is excluded, and the heterocyclic ring can otherwise be substituted with the following groups:
(C₁-C₃) alkoxy, phenylalkyl with 1-4 C atoms in the alkyl part, phenyl, optionally substituted with 1 or more - preferably only 1 - of the groups:
(C₁-C₃) alkyl, OH, (C₁-C₃) alkoxy, (C₁-C₃) alkoxy-COOH, (C₁-C₃) alkoxy-COO (C₁-C₄) alkyl, O-SO₂-C₆H₅
O-SO₂-C₆H₄CH₃, wherein R ^{1 'has} the same meaning as R¹ and can also be H, and R² and R³ have the abovementioned meaning and the ring S atom - if present - also to the sulfoxide (SO) - or sulfone (SO₂) form can be oxidized, and their physiologically tolerable salts. 2. Imidazole compounds according to claim 1, characterized in that in formula I there is at least one of the following features:
a) R¹ = CH₃ or C₂H₅,
b) R², R³ = identical or different and each H, Cl or CH₃, and
c) the -SO₂X radical is in the 2- or 4-position of the imidazole ring. 3. imidazole compounds according to claim 1 or 2, characterized in that the rest with R⁴ = H and
R⁵ = (C₂-C₅) alkyl, in which a phenylene radical is optionally between 2 carbon atoms and whose (aliphatic) carbon atoms are substituted with a total of 1 or 2 - preferably only with 1 - of the following groups: hydroxyphenyl C₆H₄OH, CN , (C₂-C₃) alkynyl, NH₂
NHR⁶
N (R⁶) ₂
wherein R⁶ = identical or different radicals of the type (C₁-C₃) alkyl, (C₂-C₄) alkoxyalkyl and benzyl;
monocyclic 5- to 6-membered saturated heterocyclic radical from the group: or R⁴ and R⁵ together with the amide N atom to which they are attached form a saturated 6-membered heterocyclic ring of the type and their physiologically tolerable salts. 4. N- (2-morpholinoethyl) -1-methyl-2-imidazolesulfonic acid amide = compound of formula I according to claim 1, wherein
R¹ = CH₃
R² = R³ = H,
SO₂X group in 2 position and and their physiologically tolerable salts. 5. N- (3-morpholinopropyl) -1-methyl-4-imidazolesulfonic acid amide = compound of formula I according to claim 1, wherein
R¹ = CH₃,
R² = R³ = H,
SO₂X group in 4 position and and their physiologically tolerable salts. 6. A process for the preparation of the imidazole compounds of the formula I as defined in one or more of claims 1-5 and, if appropriate, their physiologically tolerable salts, characterized in that
a) an imidazole derivative of the general formula III in which R¹, R² and R³ have the meaning given for formula I, and one of the positions 4 or 5 is unsubstituted, is converted into the compounds of the formula Ia by sulfonation, wherein R¹, R² and R³ also have the meaning given for formula I,
or
b) an imidazole derivative of the general formula IV in which R¹ and R² have the meaning given for formula I, one of positions 4 and 5 carries a halogen substituent Hal (Cl, Br, J) and the other is unsubstituted, converted by sulfonation and subsequent hydrogenolytic dehalogenation into a compound of formula Ib (Meaning of R¹ and R² as in formula I)
or
c) an imidazole derivative of the general formula V in which R¹, R² and R³ have the meaning given for formula I and Y represents halogen, preferably chlorine, hydrolyses to the imidazole sulfonic acids of formula Ia with the meanings given for R¹, R² and R³,
or
d) an imidazole derivative of the general formula VI or VI ′ in which R¹, R² and R³ have the meaning given for formula I, oxidized to the corresponding imidazole sulfonic acid (formula Ia),
or
e) an imidazolesulfonic acid halide of the general formula V (see variant c), with an amine of the formula H-II in which R⁴ and R⁵ have the same meaning as in formula II (see claim 1), are converted to the sulfonamides of the formula Ic wherein R¹ to R⁵ have the meanings given in the formulas I and II,
or
f) imidazole derivatives of the general formula VII, wherein R¹ and R² have the meaning given in formula I and Y is the same or different halogen atoms (Cl, Br, J), reacted with amines of the formula H-II and then subjected to hydrogenolytic dehalogenation to the 4- or 5-position to obtain unsubstituted sulfonamides of the formula Id with the meanings given in Claim 1 for R¹ and R² (Meaning of R¹, R², R⁴ and R⁵ as in formulas I and II),
or
g) an imidazole sulfonyl halide of the general formula V (see variant c) with a trialkylsilylamine of the formula VIII wherein R⁴ and R⁵ have the meaning given in formula II and more preferably (C₁-C₃) alkyl radical is the methyl radical, is reacted to give the sulfonamides of the formula Ic (see variant e),
or
h) for the preparation of compounds of the formula I - wherein X = -N (R⁴) R⁵ (formula II) and R⁴ carries at least 1 NH₂ group and / or R⁵ at least one primary or secondary amino group, amines of the formula H-N (R⁴) R⁵, which carry at least one N-protected, - preferably N-benzylated - corresponding amino group on their residues R⁴ and / or R⁵, reacted with the imidazole sulfonyl halides of the formula V (see variant c) and the sulfonamides formed then by the protective group liberated,
or
i) for the preparation of compounds of the general formula I in which X = -N (R⁴) R⁵ (formula II) and at least one of the radicals R⁴ and R⁵ carries at least 1 primary amino group, imidazolesulfonyl halides of the formula V (see variant c) with corresponding aminonitriles reacted and reduced the sulfonylaminonitriles thus obtained to the amino compounds,
or
j) for the preparation of imidazole compounds of the general formula I, wherein X = -N (R⁴) R⁵ and R⁵ carries at least one quaternary amino group -N⊕ (R⁶) ₃, in which the radicals R⁶ can be identical or different, an imidazole compound of the formula I, wherein X = -N (R⁴) R⁵ and R⁵ carries at least one tertiary amino group -N (R⁶) ₂, alkylated with an alkylating agent,
or
k) for the preparation of imidazole compounds of the general formula I in which X = -N (R⁴) R⁵ and R⁵ or R⁴ and R⁵ together contain one or more sulfoxide or sulfone groups, imidazole compounds of the general formula I in which X = -N (R⁴) R⁵ and R⁵ or R⁴ + R⁵ together contain one or more sulfide groups, oxidized to the corresponding sulfoxides or sulfones,
or
l) for the preparation of imidazole compounds of the formula I in which X = -N (R⁴) R⁵ and R⁵ or R⁴ and R⁵ together contain a phenol ether group, imidazole compounds of the general formula I in which X = -N (R⁴) R⁵ and R⁵ or R⁴ + R⁵ together carry at least one aryl radical substituted with one or more phenolic hydroxyl groups, alkylated with alkylating reagents, preferably ω-halogen fatty acid derivatives, to give the corresponding phenol ethers which, in the case of ω-fatty acid esters, also hydrolysis or aminolysis to give the corresponding carboxylic acids or Can be subjected to carboxamides,
or
m) for the preparation of imidazole compounds of the formula I in which X = -N (R⁴) R⁵ and R⁵ or R⁴ + R⁵ together contain a phenol ester group, the same starting imidazole compounds as for variant 1 with acylating reagents - preferably with (C₁-C₄) - Alkylcarboxylic acid chlorides, benzene and toluenesulfonic acid chlorides and imidazolesulfonic acid halides of the general formula V (see variant c), in which R¹, R² and R³ have the same meaning as in formula I and R¹ can also be hydrogen - to give the corresponding phenol esters,
and the compounds of the formula I formed in all process variants - if these are not already obtained in the form of physiologically tolerable salts - are optionally converted into such. 7. Compounds of formula I and their physiological compatible salts according to one or more of the Claims 1-5 or as received by the method according to claim 6 for use as a remedy. 8. Medicinal product characterized by a content of at least one compound of formula I according to the Definition in one or more of claims 1-5 and / or at least one of their physiological compatible salts and / or at least one after the A method according to claim 6 produced compound. 9. Medicament according to claim 8, characterized in that they are used for the prophylaxis and / or therapy of Circulatory disorders, especially disorders of the Microcirculation, as well as the resulting Diseases are determined. 10. Process for the manufacture of the medicament according to Claim 8 or 9, characterized in that one at least one compound of formula I according to the Definition in one or more of claims 1-5 and / or at least one of their physiological compatible salts and / or at least one after the Method according to claim 6 obtained with usual carrier and optionally additional and Brings excipients in a suitable dosage form. 11. Use of the compounds of formula I according to Definition in one or more of claims 1-5 and / or at least one according to the method Claim 6 compound obtained for prophylaxis and / or Therapy of circulatory disorders, especially of Disorders of the microcirculation, as well as the resulting resulting diseases.   12. 1-methyl, 1,2-dimethyl and 1-ethyl-4-imidazole sulfonic acid chloride. 13. A process for the preparation of the compounds mentioned in claim 11, characterized in that

• a) 1-methyl- or 1,2-dimethyl- or 1-ethyl-imidazole with chlorosulfonic acid ClSO₃H, optionally with the subsequent addition of SOCl₂, brings to reaction, or that one
• b) 1-methyl or 1,2-methyl or 1-ethyl-4-mercapto-imidazole with Cl₂ oxidizing chlorinated.